Molecular pathogenesis of human hepatocellular carcinoma

被引:1187
作者
Thorgeirsson, SS [1 ]
Grisham, JW
机构
[1] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/ng0802-339
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hepatocarcinogenesis is a slow process during which genomic changes progressively alter the hepatocellular phenotype to produce cellular intermediates that evolve into hepatocellular carcinoma. During the long pre-neoplastic stage, in which the liver is often the site of chronic hepatitis, cirrhosis, or both, hepatocyte cycling is accelerated by upregulation of mitogenic pathways, in part through epigenetic mechanisms. This leads to the production of monoclonal populations of aberrant and dysplastic hepatocytes that have telomere erosion and telomerase re-expression, sometimes microsatellite instability, and occasionally structural aberrations in genes and chromosomes. Development of dysplastic hepatocytes in foci and nodules and emergence of hepatocellular carcinoma are associated with the accumulation of irreversible structural alterations in genes and chromosomes, but the genomic basis of the malignant phenotype is heterogeneous. The malignant hepatocyte phenotype may be produced by the disruption of a number of genes that function in different regulatory pathways, producing several molecular variants of hepatocellular carcinoma. New strategies should enable these variants to be characterized.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 110 条
[31]  
2-6
[32]   Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: Comparison of loss of heterozygosity and replication error [J].
Kawai, H ;
Suda, T ;
Aoyagi, Y ;
Isokawi, O ;
Mita, Y ;
Waguri, N ;
Kuroiwa, T ;
Igarashi, M ;
Tsukada, K ;
Mori, S ;
Shimizu, T ;
Suzuki, Y ;
Abe, Y ;
Takahashi, T ;
Nomoto, M ;
Asakura, H .
HEPATOLOGY, 2000, 31 (06) :1246-1250
[33]  
KAWAKITA N, 1992, AM J PATHOL, V140, P513
[34]   Comparative hepatocellular cancer genetics [J].
Kemp, CJ .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (04) :975-977
[35]  
Kitamoto M, 1999, CANCER, V85, P245, DOI 10.1002/(SICI)1097-0142(19990101)85:1<245::AID-CNCR37>3.0.CO
[36]  
2-9
[37]   Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma [J].
Kondo, Y ;
Kanai, Y ;
Sakamoto, M ;
Mizokami, M ;
Ueda, R ;
Hirohashi, S .
HEPATOLOGY, 2000, 32 (05) :970-979
[38]   Alterations of P19ARF in rodent hepatoma cell lines but not in human primary liver cancer [J].
Laes, JF ;
Parada, LA ;
Johansson, B ;
Levan, G ;
Szpirer, C ;
Szpirer, T .
CANCER GENETICS AND CYTOGENETICS, 2000, 117 (02) :118-124
[39]  
Lau WY, 2000, ONCOL RES, V12, P59
[40]  
Lin CH, 2001, CANCER RES, V61, P4238